Posted by Michael Wonder on 30 Aug 2022
EMA announces withdrawal of two submissions for cancer medicines
30 August 2022 - The information is somewhat buried on the EMA website.
The EMA has published questions and answers on the withdrawal of two submissions for two cancer medicines:
- Mobocertinib succinate (Exkivity) for patients with non-small-cell lung cancer
- Surufatinib (Sevsury) for patients with a progressive neuroendocrine tumour.
